{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"OG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"OG001","title":"Combination"}],"populationDescription":"Data was not collected as the trial was halted early after a preplanned interim futility analysis","reportingStatus":"POSTED","timeFrame":"1 year","title":"Expression of PD-1, PD-L1 and Tumor Infiltrating Lymphocytes (TIL) in Pre-treatment Tumor Specimens","type":"SECONDARY"}